Current immunotherapy of multiple sclerosis and future challenges: Relevance of immune-mediated repair

Current Pharmaceutical Biotechnology

Volumn 13, Issue 8, 2012, Pages 1409-1417

  Carrithers, Michael D ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Brain; Demyelination; Immune surveillance; Innate immunity; Interferon; Lymphocyte; Natalizumab

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; LAQUINIMOD; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PLACEBO; RITUXIMAB; TOLL LIKE RECEPTOR;

ADD ON THERAPY; ARTICLE; AUTOIMMUNE THYROIDITIS; BRADYCARDIA; CARDIOMYOPATHY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GENE EXPRESSION; HERPES SIMPLEX ENCEPHALITIS; HERPES ZOSTER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; INFECTION; INNATE IMMUNITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NEOPLASM; NONHUMAN; OPPORTUNISTIC INFECTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SIDE EFFECT; SKIN CANCER; TISSUE REPAIR; TREATMENT DURATION; VIRUS REACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS;

EID: 84861689883     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800784781     Document Type: Article

References (96)

1. Noseworthy, J. H.; Lucchinetti, C.; Rodriguez, M.; Weinshenker, B. G. Multiple sclerosis. N. Engl. J. Med., 2000, 343 (13), 938-952.
2. Lublin, F. D.; Reingold, S. C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology, 1996, 46 (4), 907-911.
3. Weinshenker, B. G.; Bass, B.; Rice, G. P.; Noseworthy, J.; Carriere, W.; Baskerville, J.; Ebers, G. C. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain, 1989, 112 (Pt 1), 133-146.
4. Jacobs, L. D.; Wende, K. E.; Brownscheidle, C. M.; Apatoff, B.; Coyle, P. K.; Goodman, A.; Gottesman, M. H.; Granger, C. V.; Greenberg, S. J.; Herbert, J.; Krupp, L.; Lava, N. S.; Mihai, C.; Miller, A. E.; Perel, A.; Smith, C. R.; Snyder, D. H. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult. Scler. 1999, 5 (5), 369-376.
5. Polman, C. H.; Reingold, S. C.; Edan, G.; Filippi, M.; Hartung, H. P.; Kappos, L.; Lublin, F. D.; Metz, L. M.; McFarland, H. F.; O'Connor, P. W.; Sandberg-Wollheim, M.; Thompson, A. J.; Weinshenker, B. G.; Wolinsky, J. S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann. Neurol., 2005, 58 (6), 840-846.
6. Jacobs, L. D.; Beck, R. W.; Simon, J. H.; Kinkel, R. P.; Brownscheidle, C. M.; Murray, T. J.; Simonian, N. A.; Slasor, P. J.; Sandrock, A. W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 2000, 343 (13), 898-904.
7. Tanaka, R.; Iwasaki, Y.; Koprowski, H. Ultrastructural studies of perivascular cuffing cells in multiple sclerosis brain. Am. J. Pathol. 1975, 81 (3), 467-478.
8. Lucchinetti, C.; Bruck, W.; Parisi, J.; Scheithauer, B.; Rodriguez, M.; Lassmann, H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47 (6), 707-717.
9. Henderson, A. P.; Barnett, M. H.; Parratt, J. D.; Prineas, J. W. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann. Neurol. 2009, 66 (6), 739-753.
10. Zhang, J.; Markovic-Plese, S.; Lacet, B.; Raus, J.; Weiner, H. L.; Hafler, D. A. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 1994, 179 (3), 973-984.
11. Ebers, G.C.; Kukay, K.; Bulman, D.E.; Sadovnick, A.D.; Rice, G.; Anderson, C.; Armstrong, H.; Cousin, K.; Bell, R. B.; Hader, W.; Paty, D. W.; Hashimoto, S.; Oger, J.; Duquette, P.; Warren, S.; Gray, T.; O'Connor, P.; Nath, A.; Auty, A.; Metz, L.; Francis, G.; Paulseth, J.E.; Murray, T.J.; Pryse-Phillips, W.; Nelson, R.; Freedman, M.; Brunet, D.; Bouchard, J.P.; Hinds, D.; Risch, N. A full genome search in multiple sclerosis. Nat. Genet. 1996, 13 (4), 472-476.
12. Haines, J.L.; Ter-Minassian, M.; Bazyk, A.; Gusella, J.F.; Kim, D.J.; Terwedow, H.; Pericak-Vance, M.A.; Rimmler, J.B.; Haynes, C.S.; Roses, A.D.; Lee, A.; Shaner, B.; Menold, M.; Seboun, E.; Fitoussi, R.P.; Gartioux, C.; Reyes, C.; Ribierre, F.; Gyapay, G.; Weissenbach, J.; Hauser, S. L.; Goodkin, D.E.; Lincoln, R.; Usuku, K.; Oksenberg, J.R. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat. Genet. 1996, 13 (4), 469-471.
13. Sawcer, S.; Jones, H.B.; Feakes, R.; Gray, J.; Smaldon, N.; Chataway, J.; Robertson, N.; Clayton, D.; Goodfellow, P.N.; Compston, A. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat. Genet., 1996, 13 (4), 464-468.
14. Hafler, D.A.; Compston, A.; Sawcer, S.; Lander, E.S.; Daly, M.J.; De Jager, P. L.; de Bakker, P.I.; Gabriel, S.B.; Mirel, D.B.; Ivinson, A.J.; Pericak-Vance, M.A.; Gregory, S.G.; Rioux, J.D.; McCauley, J.L.; Haines, J.L.; Barcellos, L.F.; Cree, B.; Oksenberg, J.R.; Hauser, S.L. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med., 2007, 357 (9), 851-862.
15. Filippini, G.; Brusaferri, F.; Sibley, W.A.; Citterio, A.; Ciucci, G.; Midgard, R.; Candelise, L. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst. Rev., 2000, (4), CD001331.
16. Frohman, E.M.; Shah, A.; Eggenberger, E.; Metz, L.; Zivadinov, R.; Stuve, O. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics, 2007, 4 (4), 618-626.
17. Casetta, I.; Iuliano, G.; Filippini, G. Azathioprine for multiple sclerosis. Cochrane Database Syst. Rev., 2007, (4), CD003982.
18. Klawiter, E.C.; Cross, A.H.; Naismith, R.T. The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%? Neurology, 2009, 73 (12), 984-990.
19. Giovannoni, G.; Comi, G.; Cook, S.; Rammohan, K.; Rieckmann, P.; Soelberg Sorensen, P.; Vermersch, P.; Chang, P.; Hamlett, A.; Musch, B.; Greenberg, S.J. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med., 2010, 362 (5), 416-426.
20. Askenase, P.W.; Hayden, B.J.; Gershon, R.K. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J. Exp. Med. 1975, 141 (3), 697-702.
21. Brode, S.; Cooke, A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit. Rev. Immunol., 2008, 28 (2), 109-126.
22. Krishnan, C.; Kaplin, A.I.; Brodsky, R.A.; Drachman, D.B.; Jones, R.J.; Pham, D.L.; Richert, N.D.; Pardo, C.A.; Yousem, D.M.; Hammond, E.; Quigg, M.; Trecker, C.; McArthur, J.C.; Nath, A.; Greenberg, B.M.; Calabresi, P.A.; Kerr, D.A. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch. Neurol., 2008, 65 (8), 1044-1051.
23. Weiner, H.L.; Mackin, G.A.; Orav, E.J.; Hafler, D.A.; Dawson, D.M.; LaPierre, Y.; Herndon, R.; Lehrich, J.R.; Hauser, S.L.; Turel, A. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993, 43 (5), 910-918.
24. Marriott, J.J.; Miyasaki, J.M.; Gronseth, G.; O'Connor, P. W. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 2010, 74 (18), 1463-1470.
25. Hartung, H. P.; Gonsette, R.; Konig, N.; Kwiecinski, H.; Guseo, A.; Morrissey, S.P.; Krapf, H.; Zwingers, T. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360 (9350), 2018-2025.
26. Bourdette, D.; Whitham, R. Immunotherapy and multiple sclerosis: The devil is in the details. Neurology, 2010, 74 (18), 1410-1411.
27. Capobianco, M.; Malucchi, S.; Ulisciani, S.; Fava, C.; Cambrin, G.R.; Avonto, L.; Saglio, G.; Bertolotto, A. Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis. Neurol. Sci., 2008, 29 (3), 185-187.
28. Rubin, B.Y.; Gupta, S.L. Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents. Proc. Natl. Acad. Sci., U S A 1980, 77 (10), 5928-5932.
29. Nathan, C.F.; Murray, H.W.; Wiebe, M.E.; Rubin, B.Y. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med., 1983, 158 (3), 670-689.
30. Scarisbrick, I.A.; Rodriguez, M. Hit-Hit and hit-Run: viruses in the playing field of multiple sclerosis. Curr. Neurol. Neurosci. Rep., 2003, 3 (3), 265-271.
31. Panitch, H.S.; Hirsch, R.L.; Haley, A.S.; Johnson, K.P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet, 1987, 1 (8538), 893-895.
32. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology, 1993, 43 (4), 655-661.
33. Jacobs, L.D.; Cookfair, D.L.; Rudick, R.A.; Herndon, R.M.; Richert, J.R.; Salazar, A.M.; Fischer, J.S.; Goodkin, D.E.; Granger, C.V.; Simon, J.H. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Mult. Scler., 1995, 1 (2), 118-135.
34. Panitch, H.; Goodin, D.S.; Francis, G.; Chang, P.; Coyle, P.K.; O'Connor, P.; Monaghan, E.; Li, D.; Weinshenker, B. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology, 2002, 59 (10), 1496-1506.
35. Cohen, J.A.; Imrey, P.B.; Calabresi, P.A.; Edwards, K.R.; Eickenhorst, T.; Felton, W.L., 3rd; Fisher, E.; Fox, R.J.; Goodman, A.D.; Hara-Cleaver, C.; Hutton, G. J.; Mandell, B.F.; Scott, T.F.; Zhang, H.; Apperson-Hansen, C.; Beck, G.J.; Houghtaling, P.L.; Karafa, M.T.; Stadtler, M., Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology, 2009, 72 (6), 535-541.
36. Teitelbaum, D.; Meshorer, A.; Hirshfeld, T.; Arnon, R.; Sela, M., Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol., 1971, 1 (4), 242-248.
37. Johnson, K.P.; Brooks, B.R.; Cohen, J.A.; Ford, C.C.; Goldstein, J.; Lisak, R.P.; Myers, L.W.; Panitch, H.S.; Rose, J.W.; Schiffer, R.B. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology, 1995, 45 (7), 1268-1276.
38. Mikol, D. D.; Barkhof, F.; Chang, P.; Coyle, P. K.; Jeffery, D. R.; Schwid, S. R.; Stubinski, B.; Uitdehaag, B.M. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol., 2008, 7 (10), 903-914.
39. O'Connor, P.; Filippi, M.; Arnason, B.; Comi, G.; Cook, S.; Goodin, D.; Hartung, H.P.; Jeffery, D.; Kappos, L.; Boateng, F.; Filippov, V.; Groth, M.; Knappertz, V.; Kraus, C.; Sandbrink, R.; Pohl, C.; Bogumil, T.; Harung, H.P. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsingremitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol., 2009, 8 (10), 889-897.
40. Stuve, O.; Dooley, N.P.; Uhm, J.H.; Antel, J.P.; Francis, G.S.; Williams, G.; Yong, V.W., Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 1996, 40 (6), 853-863.
41. Rudick, R.A.; Carpenter, C.S.; Cookfair, D.L.; Tuohy, V.K.; Ransohoff, R. M. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology, 1993, 43 (10), 2080-2087.
42. Wandinger, K. P.; Sturzebecher, C.S.; Bielekova, B.; Detore, G.; Rosenwald, A.; Staudt, L.M.; McFarland, H.F.; Martin, R. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 2001, 50 (3), 349-357.
43. Schmied, M.; Duda, P.W.; Krieger, J.I.; Trollmo, C.; Hafler, D.A., In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis. Clin. Immunol., 2003, 106 (3), 163-174.
44. Duda, P.W.; Schmied, M.C.; Cook, S.L.; Krieger, J.I.; Hafler, D.A. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest., 2000, 105 (7), 967-976.
45. Fleming, J.O.; Carrithers, M.D. Diagnosis and management of multiple sclerosis: a handful of patience. Neurology, 2010, 74 (11), 876-877.
46. Gajofatto, A.; Bacchetti, P.; Grimes, B.; High, A.; Waubant, E. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult. Scler., 2009, 15 (1), 50-58.
47. Yednock, T.A.; Cannon, C.; Fritz, L.C.; Sanchez-Madrid, F.; Steinman, L.; Karin, N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature, 1992, 356 (6364), 63-66.
48. Polman, C. H.; O'Connor, P.W.; Havrdova, E.; Hutchinson, M.; Kappos, L.; Miller, D.H.; Phillips, J.T.; Lublin, F.D.; Giovannoni, G.; Wajgt, A.; Toal, M.; Lynn, F.; Panzara, M.A.; Sandrock, A.W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med., 2006, 354 (9), 899-910.
49. Rudick, R. A.; Stuart, W. H.; Calabresi, P. A.; Confavreux, C.; Galetta, S. L.; Radue, E. W.; Lublin, F.D.; Weinstock-Guttman, B.; Wynn, D.R.; Lynn, F.; Panzara, M.A.; Sandrock, A.W. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med., 2006, 354 (9), 911-923.
50. Berger, J.R.; Koralnik, I.J., Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences. N. Engl. J. Med., 2005, 353 (4), 414-416.
51. Kleinschmidt-DeMasters, B.K.; Tyler, K.L., Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 2005, 353 (4), 369-374.
52. Langer-Gould, A.; Atlas, S.W.; Green, A.J.; Bollen, A.W.; Pelletier, D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med., 2005, 353 (4), 3753-3781.
53. Van Assche, G.; Van Ranst, M.; Sciot, R.; Dubois, B.; Vermeire, S.; Noman, M.; Verbeeck, J.; Geboes, K.; Robberecht, W.; Rutgeerts, P. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 2005, 353 (4), 362-368.
54. Clifford, D.B.; De Luca, A; Simpson, D.M.; Arendt, G.; Giovannoni, G.; Nath, A., Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol., 2010, 9 (4), 438-446.
55. Hauser, S. L.; Waubant, E.; Arnold, D.L.; Vollmer, T.; Antel, J.; Fox, R.J.; Bar-Or, A.; Panzara, M.; Sarkar, N.; Agarwal, S.; Langer-Gould, A.; Smith, C. H., B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358 (7), 676-688.
56. Hawker, K.; O'Connor, P.; Freedman, M.S.; Calabresi, P.A.; Antel, J.; Simon, J.; Hauser, S.; Waubant, E.; Vollmer, T.; Panitch, H.; Zhang, J.; Chin, P.; Smith, C.H., Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol., 2009, 66 (4), 460-471.
57. Gea-Banacloche, J.C., Rituximab-associated infections. Semin. Hematol., 2010, 47 (2), 187-198.
58. Coles, A.J.; Compston, D.A.; Selmaj, K.W.; Lake, S.L.; Moran, S.; Margolin, D.H.; Norris, K.; Tandon, P.K. Alemtuzumab VS. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med., 2008, 359 (17), 1786-1801.
59. Bielekova, B.; Richert, N.; Howard, T.; Blevins, G.; Markovic-Plese, S.; McCartin, J.; Frank, J.A.; Wurfel, J.; Ohayon, J.; Waldmann, T.A.; McFarland, H.F.; Martin, R., Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl. Acad. Sci. U S A., 2004, 101 (23), 8705-8708.
60. Oh, U.; Blevins, G.; Griffith, C.; Richert, N.; Maric, D.; Lee, C. R.; McFarland, H.; Jacobson, S., Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch. Neurol. 2009, 66 (4), 471-479.
61. Rose, J. W.; Burns, J. B.; Bjorklund, J.; Klein, J.; Watt, H.E.; Carlson, N.G., Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology, 2007, 69 (8), 785-789.
62. Wynn, D.; Kaufman, M.; Montalban, X.; Vollmer, T.; Simon, J.; Elkins, J.; O'Neill, G.; Neyer, L.; Sheridan, J.; Wang, C.; Fong, A.; Rose, J.W. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebocontrolled, add-on trial with interferon beta. Lancet Neurol., 2010, 9 (4), 381-390.
63. Bielekova, B.; Catalfamo, M.; Reichert-Scrivner, S.; Packer, A.; Cerna, M.; Waldmann, T.A.; McFarland, H.; Henkart, P.A.; Martin, R. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. U S A., 2006, 103 (15), 5941-5946.
64. Mandala, S.; Hajdu, R.; Bergstrom, J.; Quackenbush, E.; Xie, J.; Milligan, J.; Thornton, R.; Shei, G.J.; Card, D.; Keohane, C.; Rosenbach, M.; Hale, J.; Lynch, C.L.; Rupprecht, K.; Parsons, W.; Rosen, H., Alteration of lymphocyte trafficking by sphingosine-1- phosphate receptor agonists. Science, 2002, 296 (5566), 346-349.
65. Kappos, L.; Radue, E.W.; O'Connor, P.; Polman, C.; Hohlfeld, R.; Calabresi, P.; Selmaj, K.; Agoropoulou, C.; Leyk, M.; Zhang-Auberson, L.; Burtin, P. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med., 2010, 362 (5), 387-401.
66. Cohen, J.A.; Barkhof, F.; Comi, G.; Hartung, H.P.; Khatri, B.O.; Montalban, X.; Pelletier, J.; Capra, R.; Gallo, P.; Izquierdo, G.; Tiel-Wilck, K.; de Vera, A.; Jin, J.; Stites, T.; Wu, S.; Aradhye, S.; Kappos, L., Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362 (5), 402-415.
67. Sipe, J.C.; Romine, J.S.; Koziol, J.A.; McMillan, R.; Zyroff, J.; Beutler, E., Cladribine in treatment of chronic progressive multiple sclerosis. Lancet, 1994, 344 (8914), 9-13.
68. Beutler, E.; Sipe, J.C.; Romine, J.S.; Koziol, J.A.; McMillan, R.; Zyroff, J., The treatment of chronic progressive multiple sclerosis with cladribine. Proc. Natl. Acad. Sci. U S A., 1996, 93 (4), 1716-1720.
69. Rice, G.P.; Filippi, M.; Comi, G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology, 2000, 54 (5), 1145-1155.
70. Brunmark, C.; Runstrom, A.; Ohlsson, L.; Sparre, B.; Brodin, T.; Astrom, M.; Hedlund, G. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2002, 130 (1-2), 163-172.
71. Tselis, A. Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis. Curr. Opin. Investig. Drugs, 2010, 11 (5), 577-585.
72. Polman, C.; Barkhof, F.; Sandberg-Wollheim, M.; Linde, A.; Nordle, O.; Nederman, T. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology, 2005, 64 (6), 987-991.
73. Comi, G.; Pulizzi, A.; Rovaris, M.; Abramsky, O.; Arbizu, T.; Boiko, A.; Gold, R.; Havrdova, E.; Komoly, S.; Selmaj, K.; Sharrack, B.; Filippi, M. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebocontrolled phase IIb study. Lancet, 2008, 371 (9630), 2085-2092.
74. Litjens, N.H.; Nibbering, P.H.; Barrois, A.J.; Zomerdijk, T.P.; Van Den Oudenrijn, A.C.; Noz, K.C.; Rademaker, M.; Van De Meide, P.H.; Van Dissel, J.T.; Thio, B. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br. J. Dermatol. 2003, 148 (3), 444-451.
75. Meili-Butz, S.; Niermann, T.; Fasler-Kan, E.; Barbosa, V.; Butz, N.; John, D.; Brink, M.; Buser, P.T.; Zaugg, C.E., Dimethyl fumarate, a small molecule drug for psoriasis, inhibits Nuclear Factor-kappaB and reduces myocardial infarct size in rats. Eur. J. Pharmacol., 2008, 586 (1-3), 251-258.
76. Kappos, L.; Gold, R.; Miller, D.H.; Macmanus, D.G.; Havrdova, E.; Limmroth, V.; Polman, C.H.; Schmierer, K.; Yousry, T.A.; Yang, M.; Eraksoy, M.; Meluzinova, E.; Rektor, I.; Dawson, K.T.; Sandrock, A.W.; O'Neill, G.N. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet, 2008, 372 (9648), 1463-1472.
77. Carrithers, M.D.; Visintin, I.; Kang, S.J.; Janeway, C.A., Jr., Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 2000, 123 (Pt 6), 1092-1101.
78. Ransohoff, R.M.; Kivisakk, P.; Kidd, G., Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol., 2003, 3 (7), 569-581.
79. Reboldi, A.; Coisne, C.; Baumjohann, D.; Benvenuto, F.; Bottinelli, D.; Lira, S.; Uccelli, A.; Lanzavecchia, A.; Engelhardt, B.; Sallusto, F., C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol., 2009, 10 (5), 514-523.
80. Chatterjee, G.; Carrithers, L.M.; Carrithers, M.D. Epithelial V-like antigen regulates permeability of the blood-CSF barrier. Biochem. Biophys. Res. Commun., 2008, 372 (3), 412-417.
81. D'Souza-Schorey, C. Disassembling adherens junctions: breaking up is hard to do. Trends Cell Biol., 2005, 15 (1), 19-26.
82. Lilien, J.; Balsamo, J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of betacatenin. Curr. Opin. Cell Biol., 2005, 17 (5), 459-465.
83. Carrithers, M.D.; Visintin, I.; Viret, C.; Janeway, C.S., Jr., Role of genetic background in P selectin-dependent immune surveillance of the central nervous system. J. Neuroimmunol., 2002, 129 (1-2), 51-57.
84. Kivisakk, P.; Mahad, D.J.; Callahan, M.K.; Trebst, C.; Tucky, B.; Wei, T.; Wu, L.; Baekkevold, E.S.; Lassmann, H.; Staugaitis, S.M.; Campbell, J.J.; Ransohoff, R.M., Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroids plexus and meninges via P-selectin. Proc. Natl. Acad. Sci. U S A., 2003, 100 (14), 8389-8394.
85. Guttinger, M.; Sutti, F.; Panigada, M.; Porcellini, S.; Merati, B.; Mariani, M.; Teesalu, T.; Consalez, G.G.; Grassi, F., Epithelial Vlike antigen (EVA), a novel member of the immunoglobulin superfamily, expressed in embryonic epithelia with a potential role as homotypic adhesion molecule in thymus histogenesis. J. Cell. Biol. 1998, 141 (4), 1061-1071.
86. Duncan, I.D.; Grever, W.E.; Zhang, S.C., Repair of myelin disease: strategies and progress in animal models. Mol. Med. Today, 1997, 3 (12), 554-561.
87. Kocsis, J.D.; Lankford, K.L.; Sasaki, M.; Radtke, C. Unique in vivo properties of olfactory ensheathing cells that may contribute to neural repair and protection following spinal cord injury. Neurosci. Lett., 2009, 456 (3), 137-142.
88. Frischer, J.M.; Bramow, S.; Dal-Bianco, A.; Lucchinetti, C.F.; Rauschka, H.; Schmidbauer, M.; Laursen, H.; Sorensen, P.S.; Lassmann, H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain, 2009, 132 (Pt5), 1175-1189.
89. Geissmann, F.; Manz, M.G.; Jung, S.; Sieweke, M.H.; Merad, M.; Ley, K., Development of monocytes, macrophages, and dendritec cells. Science, 2010, 327 (5966), 656-661.
90. Farez, M.F.; Quintana, F.J.; Gandhi, R.; Izquierdo, G.; Lucas, M.; Weiner, H.L., Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat. Immunol., 2009, 10 (9), 958-964.
91. Rakoff-Nahoum, S.; Medzhitov, R., Role of toll-like receptors in tissue repair and tumorigenesis. Biochemistry (Mosc) 2008, 73 (5), 555-561.
92. Wilson, M. S.; Wynn, T.A. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal. Immunol., 2009, 2 (2), 103-121.
93. Letts, G.; Loscalzo, J. Frontiers in nephrology: targeting inflammation using novel nitric oxide donors. J. Am. Soc. Nephrol., 2007, 18 (11), 2863-2869.
94. Carrithers, M.; Dib-Hajj, S.; Carrithers, L.; Tokmoulina, G.; Pypaert, M.; Jonas, E.; Waxman, S. Expression of the voltagegated sodium channel NaV1.5 in the macrophage late endosome regulates endosomal acidification. J. Immunol., 2007, 178 (12), 7822-7832.
95. Carrithers, M.D.; Chatterjee, G.; Carrithers, L.M.; Offoha, R.; Iheagwara, U.; Rahner, C.; Graham, M.; Waxman, S.G. Regulation of podosome formation in macrophages by a splice variant of the sodium channel SCN8A. J. Biol. Chem., 2009, 284 (12), 8114-8126.
96. Stegbauer, J.; Lee, D. H.; Seubert, S.; Ellrichmann, G.; Manzel, A.; Kvakan, H.; Muller, D.N.; Gaupp, S.; Rump, L.C.; Gold, R.; Linker, R.A. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc. Natl. Acad. Sci. U S A., 2009, 106 (35), 14942-14947.